Prostate Cancer and Prostatic Diseases

Papers
(The H4-Index of Prostate Cancer and Prostatic Diseases is 27. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-07-01 to 2025-07-01.)
ArticleCitations
Hypofractionated radiotherapy in elderly patients (≥75 years) affected by localized prostate cancer: a multicenter retrospective analysis from the IPOPROMISE study133
A randomized controlled trial evaluating low-intensity shockwave therapy for treatment of persistent storage symptoms following transurethral surgery for benign prostatic obstruction71
The imperative for clinical trial diversity: Perspectives in the context of prostate-specific membrane antigen-targeted imaging65
Correction to: Advances in PSMA-targeted therapy for prostate cancer65
More evidence that physical activity is beneficial for prostate cancer58
Best of 2022 in prostate cancer and prostatic diseases51
Comment on: The expression of YAP1 is increased in high-grade prostatic adenocarcinoma but is reduced in neuroendocrine prostate cancer50
The association between occupational asbestos exposure with the risk of incidence and mortality from prostate cancer: a systematic review and meta-analysis50
Reply to RE: Should LHRH therapy be continued in patients receiving Abiraterone Acetate?47
Contemporary trends in the surgical management of urinary incontinence after radical prostatectomy in the United States44
Social determinants of health: does socioeconomic status affect access to staging imaging for men with prostate cancer43
Will generalist medical artificial intelligence be the future path for health-related natural language processing models?42
Prognostic value of a baseline prognostic nutritional index for patients with prostate cancer: a systematic review and meta-analysis39
Sexual outcomes in men who have sex with men who underwent radical prostatectomy36
Germline alterations among Hispanic men with prostate cancer36
Functional outcomes and safety of focal therapy for prostate cancer: a systematic review on results and patient-reported outcome measures (PROMs)35
Perioperative outcomes of HoLEP, ThuLEP, and TURP in patients with prostate cancer: results from the GRAND study34
New BPH therapy classification: what really FITs?33
Concerns regarding prostate cancer screening guidelines in minority populations33
Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or andro29
Updated 5-year results for short course abiraterone acetate and LHRH agonist for unfavorable intermediate and favorable high-risk prostate cancer28
Integrating clinical and public health perspectives on statin use and prostate cancer risk: addressing key limitations and future directions28
The promising role of new molecular biomarkers in prostate cancer: from coding and non-coding genes to artificial intelligence approaches28
Concurrent prognostic utility of lymph node count and lymph node density for men with pathological node-positive prostate cancer27
Perceived patient burden and acceptability of MRI in comparison to PSA and ultrasound: results from the IP1-PROSTAGRAM study27
TRexit is going one step further27
Effectiveness and durability of benefit of mTOR inhibitors in a real-world cohort of patients with metastatic prostate cancer and PI3K pathway alterations27
0.077848196029663